APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hormone Refractory Prostate Cancer (HRPCA)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hormone Refractory Prostate Cancer (HRPCA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025174 pages

Choose your research edition.

Industry ResearchHormone Refractory Prostate Cancer (HRPCA) Industry Research Report 2026104 pages · $2,950 USDIndustry Growth & TrendsGlobal Hormone Refractory Prostate Cancer (HRPCA) Industry Growth and Trends Forecast to 203262 pages · $3,450 USDMarket StructureGlobal Hormone Refractory Prostate Cancer (HRPCA) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hormone Refractory Prostate Cancer (HRPCA) Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Hormone Refractory Prostate Cancer (HRPCA) Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Hormone Refractory Prostate Cancer (HRPCA) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hormone Refractory Prostate Cancer (HRPCA) include Sanofi S.A, Johnson & Johnson, Astellas Inc and Dendreon Corporation, Bayer AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Hormone Refractory Prostate Cancer (HRPCA) market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hormone Refractory Prostate Cancer (HRPCA) and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hormone Refractory Prostate Cancer (HRPCA) revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Hormone Refractory Prostate Cancer (HRPCA) market size, projected growth trends, production technologies, key applications, and end-use industries.

Hormone Refractory Prostate Cancer (HRPCA) Segment by Company

Sanofi S.A

Johnson & Johnson

Astellas Inc

Dendreon Corporation, Bayer AG

Hormone Refractory Prostate Cancer (HRPCA) Segment by Type

Vaccines

Cytotoxic Agents

Anti-Androgens

Radio-Pharmaceuticals

Hormone Refractory Prostate Cancer (HRPCA) Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Others

Hormone Refractory Prostate Cancer (HRPCA) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Refractory Prostate Cancer (HRPCA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hormone Refractory Prostate Cancer (HRPCA) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Refractory Prostate Cancer (HRPCA).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Hormone Refractory Prostate Cancer (HRPCA) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hormone Refractory Prostate Cancer (HRPCA) industry.

Chapter 3: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hormone Refractory Prostate Cancer (HRPCA)revenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Vaccines Table 3. Key Players of Cytotoxic Agents Table 4. Key Players of Anti-Androgens Table 3. Key Players of Radio-Pharmaceuticals Table 4. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Specialty Clinics Table 6. Key Players of Hospitals Table 7. Key Players of Ambulatory Surgical Centers Table 8. Key Players of Others Table 9. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2021-2026) Table 12. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2027-2032) Table 14. Hormone Refractory Prostate Cancer (HRPCA) Industry Trends Table 15. Hormone Refractory Prostate Cancer (HRPCA) Industry Drivers Table 16. Hormone Refractory Prostate Cancer (HRPCA) Industry Opportunities and Challenges Table 17. Hormone Refractory Prostate Cancer (HRPCA) Industry Restraints Table 18. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Company (2021-2026) Table 20. Global Hormone Refractory Prostate Cancer (HRPCA) Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Hormone Refractory Prostate Cancer (HRPCA) Key Company Head Office and Area Served Table 22. Global Hormone Refractory Prostate Cancer (HRPCA) Company, Product Type & Application Table 23. Global Hormone Refractory Prostate Cancer (HRPCA) Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Hormone Refractory Prostate Cancer (HRPCA) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2021-2026) Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2027-2032) Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2021-2026) Table 35. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2027-2032) Table 36. Sanofi S.A Company Information Table 37. Sanofi S.A Business Overview Table 38. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 40. Sanofi S.A Recent Development Table 41. Johnson & Johnson Company Information Table 42. Johnson & Johnson Business Overview Table 43. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 45. Johnson & Johnson Recent Development Table 46. Astellas Inc Company Information Table 47. Astellas Inc Business Overview Table 48. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 50. Astellas Inc Recent Development Table 51. Dendreon Corporation, Bayer AG Company Information Table 52. Dendreon Corporation, Bayer AG Business Overview Table 53. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio Table 55. Dendreon Corporation, Bayer AG Recent Development Table 56. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026) & (US$ Million) Table 57. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032) & (US$ Million) Table 58. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026) & (US$ Million) Table 59. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032) & (US$ Million) Table 60. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 61. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026) Table 62. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032) Table 63. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026) & (US$ Million) Table 64. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032) & (US$ Million) Table 65. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026) & (US$ Million) Table 66. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032) & (US$ Million) Table 67. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 68. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026) Table 69. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032) Table 70. China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026) & (US$ Million) Table 71. China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032) & (US$ Million) Table 72. China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026) & (US$ Million) Table 73. China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032) & (US$ Million) Table 74. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026) & (US$ Million) Table 75. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032) & (US$ Million) Table 76. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026) & (US$ Million) Table 77. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032) & (US$ Million) Table 78. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026) Table 80. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032) Table 81. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026) & (US$ Million) Table 82. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032) & (US$ Million) Table 83. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026) & (US$ Million) Table 84. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032) & (US$ Million) Table 85. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026) Table 87. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032) Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Product Image Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type: 2025 VS 2032 Figure 4. Vaccines Image Figure 5. Cytotoxic Agents Image Figure 6. Anti-Androgens Image Figure 7. Radio-Pharmaceuticals Image Figure 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application: 2025 VS 2032 Figure 10. Specialty Clinics Image Figure 11. Hospitals Image Figure 12. Ambulatory Surgical Centers Image Figure 13. Others Image Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 16. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2021-2032) Figure 23. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2021-2032) Figure 25. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 26. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032) Figure 27. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032) Figure 28. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2021-2032) Figure 29. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 30. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 32. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 33. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032) Figure 34. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032) Figure 35. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2021-2032) Figure 36. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 37. France Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 39. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 40. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 42. China Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 43. China Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032) Figure 44. China Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032) Figure 45. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 46. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032) Figure 47. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032) Figure 48. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2021-2032) Figure 49. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 53. India Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 54. Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2021-2032) Figure 59. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 64. UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 66. Chile Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Cytotoxic Agents
  • Anti-Androgens
  • Radio-Pharmaceuticals
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
Companies covered
  • Sanofi S.A
  • Johnson & Johnson
  • Astellas Inc
  • Dendreon Corporation, Bayer AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Vaccines
  5. 1.2.3 Cytotoxic Agents
  6. 1.2.4 Anti-Androgens
  7. 1.2.5 Radio-Pharmaceuticals
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Specialty Clinics
  11. 1.3.3 Hospitals
  12. 1.3.4 Ambulatory Surgical Centers
  13. 1.3.5 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Hormone Refractory Prostate Cancer (HRPCA) Growth Trends by Region
  16. 1.5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2021-2026)
  18. 1.5.3 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
  1. 2.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
  2. 2.2 Hormone Refractory Prostate Cancer (HRPCA) Industry Drivers
  3. 2.3 Hormone Refractory Prostate Cancer (HRPCA) Industry Opportunities and Challenges
  4. 2.4 Hormone Refractory Prostate Cancer (HRPCA) Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Company (2021-2026)
  2. 3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Hormone Refractory Prostate Cancer (HRPCA) Key Company Head office and Area Served
  4. 3.4 Global Hormone Refractory Prostate Cancer (HRPCA) Company, Product Type & Application
  5. 3.5 Global Hormone Refractory Prostate Cancer (HRPCA) Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Hormone Refractory Prostate Cancer (HRPCA) Tier 1, Tier 2, and Tier 3
4 Hormone Refractory Prostate Cancer (HRPCA) Market by Type
  1. 4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2032)
  3. 4.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Type (2021-2032)
5 Hormone Refractory Prostate Cancer (HRPCA) Market by Application
  1. 5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2032)
  3. 5.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sanofi S.A
  2. 6.1.1 Sanofi S.A Company Information
  3. 6.1.2 Sanofi S.A Business Overview
  4. 6.1.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  6. 6.1.5 Sanofi S.A Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Astellas Inc
  14. 6.3.1 Astellas Inc Company Information
  15. 6.3.2 Astellas Inc Business Overview
  16. 6.3.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  18. 6.3.5 Astellas Inc Recent Developments
  19. 6.4 Dendreon Corporation, Bayer AG
  20. 6.4.1 Dendreon Corporation, Bayer AG Company Information
  21. 6.4.2 Dendreon Corporation, Bayer AG Business Overview
  22. 6.4.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
  24. 6.4.5 Dendreon Corporation, Bayer AG Recent Developments
7 North America
  1. 7.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
  2. 7.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
  3. 7.2.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026)
  4. 7.2.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032)
  5. 7.2.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032)
  6. 7.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
  7. 7.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026)
  8. 7.3.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032)
  9. 7.3.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032)
  10. 7.4 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
  11. 7.4.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
  13. 7.4.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
  14. 7.4.4 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
  2. 8.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
  3. 8.2.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026)
  4. 8.2.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032)
  5. 8.2.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032)
  6. 8.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
  7. 8.3.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026)
  8. 8.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032)
  9. 8.3.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032)
  10. 8.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
  11. 8.4.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
  13. 8.4.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
  14. 8.4.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
  2. 9.2 China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
  3. 9.2.1 China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026)
  4. 9.2.2 China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032)
  5. 9.2.3 China Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032)
  6. 9.3 China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
  7. 9.3.1 China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026)
  8. 9.3.2 China Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032)
  9. 9.3.3 China Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
  2. 10.2 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
  3. 10.2.1 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026)
  4. 10.2.2 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032)
  5. 10.2.3 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032)
  6. 10.3 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
  7. 10.3.1 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026)
  8. 10.3.2 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032)
  9. 10.3.3 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032)
  10. 10.4 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
  11. 10.4.1 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
  13. 10.4.3 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
  14. 10.4.4 Asia Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst